07.18.13
Denver, Colo.-based Corgenix Medical Corp., maker of diagnostic test kits, has entered a contract manufacturing agreement with EDP Biotech Corp. in Knoxville, Tenn. EDP develops and sells immunodiagnostic tests.
Under the 10-year pact, Corgenix will manufacture and supply the ColoMarker diagnostic test, a blood test developed to detect the early stages of colon cancer. Corgenix also recently announced the expansion of its contract services business unit and launched a dedicated contract services website.
“We are pleased to enter into this mutually beneficial relationship with EDP,” said Douglass Simpson, president and CEO of Corgenix. “This reflects our strategic focus on the contract services portion of our business for diagnostic products, and it meets the increasing demand overall for contract services in the medical device and biotechnology industries.”
ColoMarker is a simple blood test designed to identify potential cases of early stage colon cancer. According to Corgenix, ColoMarker requires no advance preparation by the patient such as fasting or colon cleansing and can be added easily to the panel of blood tests routinely performed at a patient’s annual physical.
Corgenix makes specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including a non-blood-based test for aspirin effect.
Under the 10-year pact, Corgenix will manufacture and supply the ColoMarker diagnostic test, a blood test developed to detect the early stages of colon cancer. Corgenix also recently announced the expansion of its contract services business unit and launched a dedicated contract services website.
“We are pleased to enter into this mutually beneficial relationship with EDP,” said Douglass Simpson, president and CEO of Corgenix. “This reflects our strategic focus on the contract services portion of our business for diagnostic products, and it meets the increasing demand overall for contract services in the medical device and biotechnology industries.”
ColoMarker is a simple blood test designed to identify potential cases of early stage colon cancer. According to Corgenix, ColoMarker requires no advance preparation by the patient such as fasting or colon cleansing and can be added easily to the panel of blood tests routinely performed at a patient’s annual physical.
Corgenix makes specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including a non-blood-based test for aspirin effect.